Friedrich Alexander University Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2009
NCT00456092
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Friedrich-Alexander-University, Erlangen | Friedrich-Alexander University Erlangen-Nuremberg

Active Ingredients

Drugs in Phase 3 Trials (1)

cobitolimod (2 trials)

Drugs in Phase 2 Trials (1)

apremilast (otezla) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 2)

Arthritis, Psoriatic (Phase 2)

Colitis (Phase 2)

Colitis, Ulcerative (Phase 2)

Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 2